with Omnipod® 5
Helps keep you in range, day and night1,2
No multiple daily injections, tubes, or fingersticks*
Cleared for people with type 1 diabetes ages 2 years and older
The best of both worlds.
No need to compromise.
Long gone are the days of choosing between glucose results from an Automated Insulin Delivery System and freedom of a tubeless device. With Omnipod 5, you can have the best of both worlds, all in one.
More time in range
Clinical study participants showed improved time in range by 3.7 hours per day in children (2.6 hours per day in children ages 2-5.9 years) and 2.2 hours per day in adolescents and adults.1,2
Clinical study participants experienced a reduction in A1C of 0.71% in children (0.5% in children ages 2-5.9 years old) and 0.38% in adolescents and adults.1,2
Adapted to you
Omnipod 5 adapts with every Pod change to meet your unique insulin needs and adjusts insulin using a customized Target Glucose, not a range.
Innovation at your fingertips
Omnipod 5 boasts outstanding design and engineering, recognized by the CES Innovation Awards in 2022.
Using SmartAdjust™ technology, the Pod and Dexcom G6 CGM are in constant communication, enabling automatic insulin adjustments to help improve time in range.1,2 And, you can control it all from your fingertips with the Omnipod 5 App on a compatible smartphone.†
Always adjusting so you don’t have to
Omnipod 5 automatically increases, decreases, or pauses insulin delivery every 5 minutes, helping to protect against highs and lows, day and night.1,2
See how Omnipod 5 compares
Tandem T:Slim X2
with Control-IQ technology
|Automated Insulin Delivery||✔||✔||✔|
|Zero Fingersticks* with Dexcom G6 CGM integration||✔||✔|
|Cleared for type 1 diabetes, ages 2+||✔||✔|
|Full control from compatible smartphone†‡||✔||Administer boluses|
|Customizable glucose targets§||✔|
|Pick up at your local pharmacy with no
long-term commitment or lock-in period
* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
† For a list of compatible smartphone devices, visit omnipod.com/compatibility
‡ In addition to administering and canceling boluses, Omnipod 5 users have full system functionality from a smartphone including initial system configuration, new Pod set up, insulin delivery settings adjustments, alerts & alarms acknowledgement, and more.
§ SmartAdjust™ technology uses a customizable Target Glucose between 110-150 mg/dL, adjustable in 10 mg/dL increments. Control-IQ™ uses a non-adjustable Target Glucose range of 112.5-160 mg/dL, with an option to use Sleep Activity with a range of 112.5-120 mg/dL. SmartGuard™ Auto Mode uses a non-adjustable target sensor glucose setting of 120 mg/dL.
Hear real stories
“Having control over my diabetes and my numbers—I’ve found this new confidence that I didn’t have before.”
Omnipod 5 User
Get started today – no contracts or commitments.
Omnipod 5 is available exclusively through the pharmacy channel, which means you can make the switch from multiple daily injections, a tubed pump, or another Omnipod System at any time. Simply fill out the form to get started.
Looking for more information
about Omnipod 5?
Check out the Omnipod 5 FAQs or “How to” video tutorials
*Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
†For a list of compatible smartphone devices visit omnipod.com/compatibility.
1. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Median time with low blood glucose from CGM: standard therapy = 3.43% vs. 2.46%. Sherr JL, et al. Diabetes Care (2022).
2. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Brown et al. Diabetes Care (2021).
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoRapid®, Humalog®, and Admelog®.The Omnipod 5 Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.
WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.
WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.